Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MS Awareness Week

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

Teva launches personalised digital support for MS patients

Says its MS Care Programme is the first of its kind

Sanofi reception

Sanofi licences Principia MS drug in $805m deal

Californian biotech is set to receive $765m plus in milestone payments if PRN2246 goes to market

Roche Basel Switzerland

Smartphone monitoring shows its worth in Roche MS trial

The tool uses smartphone sensors to measure neurological tests

- PMLiVE

Teva faces early rival to longer-acting Copaxone in US

US regulator approves Mylan’s MS drug

- PMLiVE

Sanofi Genzyme brings The World Vs MS to Denmark

Firm's Communiqué Award winning campaign launches in another local market

- PMLiVE

Novartis trial marks ResearchKit first in MS

ElevateMS study will allow participants to contribute from smartphones

Roche Basel Switzerland

Ocrevus off to a flying start as Roche raises 2017 forecasts

New multiple sclerosis drug posts positive results in first quarter

- PMLiVE

Merck gets CHMP backing for long-delayed oral MS drug

Cladribine, which will be branded as Mavenclad, was originally rejected by the committee in 2010

- PMLiVE

Teva drops laquinimod for most common form of MS after failed trial

CONCERTO study showed no disability progression improvements over placebo

New analysis shows emergency hospital admissions for people with Multiple Sclerosis continue to rise

Updated data published by Wilmington Healthcare and the MS Trust highlights need for more preventative care for MS patients

Wilmington Healthcare

Roche Basel Switzerland

Roche sets disruptive price for new MS drug Ocrevus in US

Firm will significantly under cut rivals like Merck's Rebif

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links